sotatercept, PL1 - Powder for injection
A011-16
Phase 2 small_molecule active
Quick answer
sotatercept, PL1 - Powder for injection for Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active